

Clinical Outcomes in HER2-low Breast Cancer Patients: Comparison with Current Classifications

Desfechos Clínicos em Pacientes com Câncer de Mama HER2-low: Comparação com as Classificações Atuais

Dido Eliphas Leão de Alencar;

<https://orcid.org/0000-0001-6022-9171>

Mestrando em Patologia da Universidade Federal de Ciências da Saúde de Porto Alegre
didoelalencar@gmail.com

Adriana Vial Roehe

<https://orcid.org/0000-0002-6294-7342>

Pós-doutorado no Instituto de Patologia na Friedrich-Alexander Universitat Erlangen-Nuremberg
avroehe@gmail.com

Introduction: Breast cancer in women is a disease with high incidence and prevalence and is the constant focus of studies aiming for a better characterization of clinical and molecular aspects in search of better therapeutic targets. The antibody-drug conjugate from the Destiny-Breast04 study showed consistent results in the treatment of carcinomas characterized as HER2-negative, raising questions regarding the current classification. There is a pursuit to understand a new category: HER2-low, which includes the classifications of 1+ and 2+. There are discrepancies in the literature regarding the differences in outcomes of this classification. **Objective:** Analyze data from breast cancer patients and compare the different clinical outcomes of HER2-low patients with the classification described in the current guidelines. **Methodology:** Cross-sectional study in which new immunohistochemical reactions were performed on 250 samples from patients with HER2-negative breast cancer, with their reclassification and analysis of clinical and morphological variables according to the database. **Results:** Partial results from patients with HER2-low show that the average age is 53 years, with a predominance of the no special type (NST) subtype. The mean tumor size is 2.3 cm, with hormonal receptor expression in 75% of cases and a proliferative index (Ki-67) of 18%. Overall survival is 46 months, with 33 months of disease-free survival. **Conclusion:** The data so far are comparable to those reported in the international literature and do not characterize a distinct entity. However, new therapies that use HER2 as a target show promising results in improving the prognosis and survival.

Key words: HER2-low, Breast cancer, Clinical outcomes, Targeted therapies, Immunohistochemistry

Área temática: Temas livres em Medicina.